Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the Introduction of New Disease-Modifying Agents

被引：0
|
作者：
Pierluigi Russo
Alessandro Capone
Andrea Paolillo
Francesco Macchia
Federica Ranzato
Gianfranco Costantino
Luca Degli Esposti
Luciano Caprino
机构：
[1] University of Rome “La Sapienza”,Department of Human Physiology and Pharmacology
[2] Economics and Outcome Research,Clicon S.r.l., Health
[3] University of Rome “La Sapienza”,Department of Neurological Sciences
[4] University of Padua,Neurologic Clinic I
[5] Ospedale Civile di Foggia,undefined
来源：
Clinical Drug Investigation | 2004年 / 24卷
关键词：
Multiple Sclerosis; Glatiramer Acetate; Oxybutynin; Tolterodine; Progressive Multiple Sclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：409 / 420
页数：11
相关论文
共 50 条
  • [41] THE COST-EFFECTIVENESS OF DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Bozkaya, D.
    Livingston, T. P.
    Migliaccio-Walle, K.
    Mehta, S.
    Odom, T.
    VALUE IN HEALTH, 2015, 18 (03) : S283 - S283
  • [42] Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
    Kalincik, Tomas
    Diouf, Ibrahima
    Sharmin, Sifat
    Malpas, Charles
    Spelman, Tim
    Horakova, Dana
    Havrdova, Eva Kubala
    Trojano, Maria
    Izquierdo, Guillermo
    Lugaresi, Alessandra
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Grammond, Pierre
    Jokubaitis, Vilija
    Van der Walt, Anneke
    Grand'Maison, Francois
    Sola, Patrizia
    Ferraro, Diana
    Shaygannejad, Vahid
    Alroughani, Raed
    Hupperts, Raymond
    Terzi, Murat
    Boz, Cavit
    Lechner-Scott, Jeannette
    Pucci, Eugenio
    Van Pesch, Vincent
    Granella, Franco
    Bergamaschi, Roberto
    Spitaleri, Daniele
    Slee, Mark
    Vucic, Steve
    Ampapa, Radek
    McCombe, Pamela
    Ramo-Tello, Cristina
    Prevost, Julie
    Olascoaga, Javier
    Cristiano, Edgardo
    Barnett, Michael
    Saladino, Maria Laura
    Sanchez-Menoyo, Jose Luis
    Hodgkinson, Suzanne
    Rozsa, Csilla
    Hughes, Stella
    Moore, Fraser
    Shaw, Cameron
    Butler, Ernest
    Skibina, Olga
    Gray, Orla
    Kermode, Allan
    NEUROLOGY, 2021, 96 (05) : E783 - E797
  • [43] Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment
    Grand'Maison, Francois
    Yeung, Michael
    Morrow, Sarah A.
    Lee, Liesly
    Emond, Francois
    Ward, Brian J.
    Laneuville, Pierre
    Schecter, Robyn
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (08) : 1419 - 1430
  • [44] EFFICACY AND SAFETY OF DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW
    Lingohr-Smith, M.
    Deitelzweig, C.
    Lin, G.
    Lin, J.
    VALUE IN HEALTH, 2021, 24 : S158 - S158
  • [45] The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review
    Shahtaheri, Rahil Sadat
    Nikfar, Shekoufeh
    Khorasani, Elahe
    Sabbagh-Baniazad, Mansoureh
    Goudarzi, Zahra
    Emamikhah, Maziar
    CURRENT JOURNAL OF NEUROLOGY, 2020, 19 (03): : 138 - 145
  • [46] The prevalence and characteristics of epilepsy in patients with relapsing-remitting multiple sclerosis treated with disease-modifying therapy
    Kolcava, J.
    Kocica, J.
    Stourac, P.
    Bednarik, J.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2020, 83 (04) : 424 - 427
  • [47] Relapsing-remitting multiple sclerosis and oligoclonal band pattern during disease-modifying drug therapy
    Mares, J
    Herzig, R
    Urbanek, K
    Bekarek, V
    Sklenarova, J
    Zapletalova, J
    Hlustik, P
    Kanovsky, P
    NEUROLOGY, 2006, 66 (05) : A371 - A371
  • [48] Matters arising: cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review
    Lazzaro, Carlo
    Bergamaschi, Roberto
    Zaffaroni, Mauro
    Totaro, Rocco
    Paolicelli, Damiano
    HEALTH ECONOMICS REVIEW, 2025, 15 (01):
  • [49] Predictors of Response to First-Line Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
    Castillo-Trivino, Tamara
    Gajofatto, Alberto
    Bacchetti, Peter
    Waubant, Emmanuelle
    NEUROLOGY, 2010, 74 (09) : A155 - A155
  • [50] Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
    Marita Zimmermann
    Elizabeth Brouwer
    Jeffrey A. Tice
    Matt Seidner
    Anne M. Loos
    Shanshan Liu
    Richard H. Chapman
    Varun Kumar
    Josh J. Carlson
    CNS Drugs, 2018, 32 : 1145 - 1157
12345